GlassScriptPhysician profile
Michael S Mcallister
NPI 1720170053
$74,213.04
in general payments reported to CMS, 2019-2025
82 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $6,878 · 2021: $6,018 · 2022: $3,969 · 2023: $5,753 · 2024: $27K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $10K · Consulting Fee: $6,725 · Travel and Lodging: $5,376 · Education: $218 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,310.00 |
| Food and Beverage | $10,109.72 |
| Consulting Fee | $6,725.00 |
| Travel and Lodging | $5,376.33 |
| Education | $217.98 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $39,512.62 | 2019-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $9,036.58 | 2019-2025 | Truqap, Imfinzi, Lynparza |
| Spectrum Pharmaceuticals INC. | $3,233.53 | 2023-2024 | Rolvedon |
| Novartis Pharmaceuticals Corporation | $2,757.93 | 2019-2025 | |
| Genentech USA, INC. | $1,877.76 | 2019-2025 | Tecentriq, Phesgo, Lunsumio |
| Exelixis INC. | $1,513.86 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $1,450.26 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $910.17 | 2019-2025 | Monjuvi, Zynyz, Monjuvi |
| Mirati Therapeutics, INC. | $863.30 | 2023 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $852.48 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Amgen INC. | $664.93 | 2019-2022 | |
| Pfizer INC. | $636.61 | 2019-2025 | |
| Celgene Corporation | $625.77 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Emd Serono, INC. | $585.10 | 2020-2025 | |
| Asd Specialty Healthcare, LLC | $568.78 | 2019-2025 |
Show all 81 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcallister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.